• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2005 年至 2015 年坦桑尼亚不合规和假冒伪劣人用药品及含禁用成分化妆品的经济成本:监管机构数据的回顾性分析。

Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority.

机构信息

Department of Global Public Health and Primary Care, Centre for International Health, University of Bergen, Bergen, Norway.

School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.

出版信息

BMJ Open. 2018 Jun 27;8(6):e021825. doi: 10.1136/bmjopen-2018-021825.

DOI:10.1136/bmjopen-2018-021825
PMID:29950474
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6020956/
Abstract

OBJECTIVE

To estimate the economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015.

DESIGN

A retrospective review of data.

SETTING

Tanzania Food and Drugs Authority and premises dealing with importations and distributions of pharmaceuticals.

ELIGIBILITY CRITERIA

Confiscation reports of substandard human medicines, falsified human medicines and cosmetics with banned ingredients.

PRIMARY AND SECONDARY OUTCOME MEASURES

Quantities and costs of pharmaceutical products, costs of transportation, storage, court cases and disposal of products.

RESULTS

The economic cost of substandard and falsified human medicines and cosmetics with banned ingredients was estimated at US$16.2 million, that is, value of substandard medicines US$13.7 million (84.4%), falsified medicines US$0.1 million (1%), cosmetics with banned ingredients US$1.3 million (8%) and other/operational costs US$1.1 million (6.6%). Some of the identified substandard and falsified human medicines include commonly used antibiotics such as phenoxymethylpenicillin, amoxicillin, cloxacillin and co-trimoxazole; antimalarials such quinine, sulfadoxine-pyrimethamine, sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine; antiretroviral drugs; antipyretics and vitamins among others.

CONCLUSION

The economic cost of substandard and falsified human medicines and cosmetics with banned ingredients represent a relatively large loss of scarce resources for a poor country like Tanzania. We believe that the observed increase in the quantities and the economic cost of these products over time could partly be due to the improvement in the regulatory capacity in terms of human resources, infrastructure and frequency of inspections.

摘要

目的

估计 2005 年至 2015 年期间坦桑尼亚不合规和假冒人用药品及含禁用成分化妆品的经济成本。

设计

数据回顾性审查。

地点

坦桑尼亚食品和药物管理局及从事药品进出口和分销的场所。

入选标准

不合规人用药品、假冒人用药品和含禁用成分化妆品的没收报告。

主要和次要结果测量

药品数量和成本、运输成本、储存成本、法庭案件和产品处置成本。

结果

不合规和假冒人用药品及含禁用成分化妆品的经济成本估计为 1620 万美元,即不合规药品价值 1370 万美元(84.4%)、假冒药品 10 万美元(1%)、含禁用成分化妆品 130 万美元(8%)和其他/运营成本 110 万美元(6.6%)。一些被识别的不合规和假冒人用药品包括常用抗生素,如苯氧甲基青霉素、阿莫西林、氯唑西林和复方磺胺甲噁唑;抗疟药,如奎宁、磺胺多辛-乙胺嘧啶、磺胺二甲嘧啶-乙胺嘧啶和青蒿琥酯-甲氟喹;抗逆转录病毒药物;解热镇痛药和维生素等。

结论

不合规和假冒人用药品及含禁用成分化妆品的经济成本对坦桑尼亚这样的贫穷国家来说是相当大的稀缺资源损失。我们认为,随着时间的推移,这些产品的数量和经济成本的增加,部分原因可能是监管能力在人力资源、基础设施和检查频率方面有所提高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6907/6020956/910e5d9d1c1e/bmjopen-2018-021825f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6907/6020956/a4913bc38964/bmjopen-2018-021825f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6907/6020956/c73602c9496a/bmjopen-2018-021825f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6907/6020956/910e5d9d1c1e/bmjopen-2018-021825f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6907/6020956/a4913bc38964/bmjopen-2018-021825f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6907/6020956/c73602c9496a/bmjopen-2018-021825f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6907/6020956/910e5d9d1c1e/bmjopen-2018-021825f03.jpg

相似文献

1
Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority.2005 年至 2015 年坦桑尼亚不合规和假冒伪劣人用药品及含禁用成分化妆品的经济成本:监管机构数据的回顾性分析。
BMJ Open. 2018 Jun 27;8(6):e021825. doi: 10.1136/bmjopen-2018-021825.
2
Fighting trafficking of falsified and substandard medicinal products in Russia.打击俄罗斯假药和劣药的非法交易。
Int J Risk Saf Med. 2015;27 Suppl 1:S37-40. doi: 10.3233/JRS-150681.
3
Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.中低收入国家不合格和假冒药品的流行情况及经济负担估计:系统评价和荟萃分析。
JAMA Netw Open. 2018 Aug 3;1(4):e181662. doi: 10.1001/jamanetworkopen.2018.1662.
4
Poor-quality antimalarials further health inequities in Uganda.劣质抗疟药物进一步加剧了乌干达的健康不平等。
Health Policy Plan. 2019 Dec 1;34(Supplement_3):iii36-iii47. doi: 10.1093/heapol/czz012.
5
The economic impact of substandard and falsified antimalarial medications in Nigeria.尼日利亚不合格和假冒抗疟药物的经济影响。
PLoS One. 2019 Aug 15;14(8):e0217910. doi: 10.1371/journal.pone.0217910. eCollection 2019.
6
Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo.模拟假冒伪劣抗疟药物对刚果民主共和国的经济影响。
Am J Trop Med Hyg. 2019 May;100(5):1149-1157. doi: 10.4269/ajtmh.18-0334.
7
Impact of substandard and falsified antimalarials in Zambia: application of the SAFARI model.赞比亚不合格和假冒抗疟药物的影响:SAFARI 模型的应用。
BMC Public Health. 2020 Jul 9;20(1):1083. doi: 10.1186/s12889-020-08852-w.
8
Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study.开发基于代理的模型评估劣药和假药对疟疾的影响:乌干达案例研究。
Malar J. 2019 Jan 9;18(1):5. doi: 10.1186/s12936-018-2628-3.
9
Usefulness of combined screening methods for rapid detection of falsified and/or substandard medicines in the absence of a confirmatory method.联合筛选方法在缺乏确证方法的情况下快速检测假药和/或劣药的有用性。
Malar J. 2019 Dec 5;18(1):403. doi: 10.1186/s12936-019-3045-y.
10
Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance.伪劣药品:案例发现和哨点监测的建议方法。
JMIR Public Health Surveill. 2021 Aug 16;7(8):e29309. doi: 10.2196/29309.

引用本文的文献

1
Strengthening regulation for medical products in Tanzania: An assessment of regulatory capacity development, 1978-2020.加强坦桑尼亚医疗产品监管:1978 - 2020年监管能力发展评估
PLOS Glob Public Health. 2024 Oct 16;4(10):e0003241. doi: 10.1371/journal.pgph.0003241. eCollection 2024.
2
A Comprehensive Assessment of Quality of Antimalarial Medicines in Mainland Tanzania: Insights from Five Years of Postmarket Surveillance.坦桑尼亚大陆抗疟药物质量的综合评估:来自五年上市后监测的见解
Am J Trop Med Hyg. 2024 Oct 1;111(6):1215-1222. doi: 10.4269/ajtmh.24-0145. Print 2024 Dec 4.
3
Off‑label and unapproved pediatric drug utilization: A meta‑analysis.

本文引用的文献

1
Antimicrobial resistance pattern: a report of microbiological cultures at a tertiary hospital in Tanzania.抗菌药物耐药模式:坦桑尼亚一家三级医院的微生物培养报告
BMC Infect Dis. 2016 Dec 13;16(1):756. doi: 10.1186/s12879-016-2082-1.
2
Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa.撒哈拉以南非洲地区与低质量抗疟药物相关的五岁以下儿童估计死亡数。
Am J Trop Med Hyg. 2015 Jun;92(6 Suppl):119-126. doi: 10.4269/ajtmh.14-0725. Epub 2015 Apr 20.
3
Reforms: a quest for efficiency or an opportunity for vested interests'? A case study of pharmaceutical policy reforms in Tanzania.
非标签和未批准的儿科药物使用情况:一项荟萃分析。
Exp Ther Med. 2024 Aug 30;28(5):412. doi: 10.3892/etm.2024.12701. eCollection 2024 Nov.
4
Improving access to medicines to reduce marketing and use of substandard and falsified medicines in Africa: Scoping review.改善非洲药品可及性以减少不合格和伪造药品的销售与使用:范围综述
J Med Access. 2024 Mar 11;8:27550834241236598. doi: 10.1177/27550834241236598. eCollection 2024 Jan-Dec.
5
Health, Economic, and Social Impacts of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review of Methodological Approaches.中低收入国家劣药和假药的健康、经济和社会影响:方法学方法的系统评价。
Am J Trop Med Hyg. 2023 Jun 20;109(2):228-240. doi: 10.4269/ajtmh.22-0525. Print 2023 Aug 2.
6
Reliability and validity of an innovative high performing healthcare system assessment tool.创新型高性能医疗保健系统评估工具的可靠性和有效性。
BMC Health Serv Res. 2023 Mar 13;23(1):242. doi: 10.1186/s12913-022-08852-z.
7
Improved knowledge on substandard and falsified (SF) medical products through a dedicated course for pharmacy students at three universities in sub-Saharan Africa.通过在撒哈拉以南非洲的三所大学为药学学生开设专门课程,提高了对劣药和假药(SF)的认识。
BMJ Glob Health. 2023 Feb;6(Suppl 3). doi: 10.1136/bmjgh-2022-009367.
8
Tanzanian primary healthcare workers' experiences of antibiotic prescription and understanding of antibiotic resistance in common childhood infections: a qualitative phenomenographic study.坦桑尼亚初级保健工作者在常见儿童感染中开具抗生素处方的经验和对抗生素耐药性的理解:定性现象学研究。
Antimicrob Resist Infect Control. 2021 Jun 27;10(1):94. doi: 10.1186/s13756-021-00952-5.
9
Development of a lateral flow dipstick for simultaneous and semi-quantitative analysis of dihydroartemisinin and piperaquine in an artemisinin combination therapy.开发一种侧向流动检测条,用于同时和半定量分析青蒿素联合疗法中的双氢青蒿素和哌喹。
Drug Test Anal. 2019 Sep;11(9):1444-1452. doi: 10.1002/dta.2656. Epub 2019 Jul 4.
改革:追求效率还是既得利益的机会?坦桑尼亚药品政策改革案例研究。
BMC Public Health. 2013 Jul 13;13:651. doi: 10.1186/1471-2458-13-651.
4
Impact of poor-quality medicines in the 'developing' world.劣质药品对“发展中”世界的影响。
Trends Pharmacol Sci. 2010 Mar;31(3):99-101. doi: 10.1016/j.tips.2009.11.005. Epub 2010 Feb 1.
5
Substandard medicines in resource-poor settings: a problem that can no longer be ignored.资源匮乏地区的劣质药品:一个不容忽视的问题。
Trop Med Int Health. 2008 Aug;13(8):1062-72. doi: 10.1111/j.1365-3156.2008.02106.x. Epub 2008 Jul 8.
6
Surveillance of antimicrobial resistance at a tertiary hospital in Tanzania.坦桑尼亚一家三级医院的抗菌药物耐药性监测。
BMC Public Health. 2004 Oct 11;4:45. doi: 10.1186/1471-2458-4-45.
7
The population dynamics of antimicrobial chemotherapy.抗菌化疗的群体动力学
Antimicrob Agents Chemother. 1997 Feb;41(2):363-73. doi: 10.1128/AAC.41.2.363.